Company intelligence / Profile preview

Elion Therapeutics

New York, New York, United Stateseliontx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Elion’s lead candidate SF001, a rationally designed polyene analog of amphotericin B with reduced toxicity, has completed a first-in-human single ascending dose study and entered multiple ascending dose studies. The compound has received FDA Fast Track and QIDP designations for early antifungal therapy and treatment of invasive aspergillosis. No efficacy data have been published yet; the program remains in early clinical development.[7][8][9]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (specifically, next-generation polyene antifungals)
Industry: Biotech

Drug pipeline

1 asset

turletricin

Partnerships

Deerfield Management Company [investor/partner; not a commercial partnership but strategic funding support][1][3]AMR Action Fund [investor/partner focused on antimicrobial resistance technologies; not a commercial partnership but strategic funding support][3]

Beyond the preview

Go deeper on Elion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elion Therapeutics.

Explore the full profile